Open AccessOral chemotherapy for second-line treatment in patients with gemcitabine-refractory advanced pancreatic cancer
Author(s) -
Sejun Park,
Hyunho Kim,
Kabsoo Shin,
Myung Ah Lee,
Tae Ho Hong
Publication year - 2019
Publication title -
world journal of gastrointestinal oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.924
H-Index - 26
ISSN - 1948-5204
DOI - 10.4251/wjgo.v11.i11.1021
Subject(s) - capecitabine , medicine , gemcitabine , irinotecan , oxaliplatin , folfirinox , pancreatic cancer , chemotherapy , refractory (planetary science) , fluorouracil , oncology , gastroenterology , antimetabolite , cancer , colorectal cancer , physics , astrobiology
There is no standard therapy for second-line treatment of gemcitabine-refractory pancreatic cancer patients with poor performance status. A combination of chemotherapy drugs 5-fluorouracil (5-FU), leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) or 5-fluorouracil/leucovorin plus nanoliposomal irinotecan can be considered as second-line treatment for such patients; however, due to toxicity, none of the regimens are recommended for patients with poor performance. Capecitabine or S-1 has relatively low toxicity and can be considered a treatment option for gemcitabine-refractory pancreatic cancer.